About.
Who we are
Genomics England
Genomics England’s delivery of the 100,000 genomes project was a major contribution to the UK becoming the first country in the world to introduce genomic medicine into routine use in its healthcare system, helping doctors deliver quicker diagnoses, more tailored treatments and more personalised care to patients. We continue to work in partnership with the NHS as we move towards bringing genomic healthcare to all who need it, and make sure that the UK’s population diversity is reflected in the data that it holds and the research that takes place with it.
​
![AdobeStock_278571483 [Converted].jpg](https://static.wixstatic.com/media/93d683_80f5bd839b214574ac4fb05d54bfce41~mv2.jpg/v1/fit/w_1915,h_1915,q_90/93d683_80f5bd839b214574ac4fb05d54bfce41~mv2.webp)
![AdobeStock_278571483 [Converted].png](https://static.wixstatic.com/media/93d683_6728b746678f411caf509317442a489a~mv2.png/v1/fit/w_1915,h_1915,q_90/93d683_6728b746678f411caf509317442a489a~mv2.webp)
![AdobeStock_278572176 [Converted]-01.png](https://static.wixstatic.com/media/93d683_ef18bf569cf941528aeccd29ef1532ac~mv2.png/v1/fit/w_1915,h_1915,q_90/93d683_ef18bf569cf941528aeccd29ef1532ac~mv2.webp)
![AdobeStock_318681604 [Converted].png](https://static.wixstatic.com/media/93d683_cfbd5fc1b99c4b5e8b89b77715b59af2~mv2.png/v1/fit/w_1920,h_1915,q_90/93d683_cfbd5fc1b99c4b5e8b89b77715b59af2~mv2.webp)
The Diverse Data Programme
The Diverse Data programme at Genomics England aims to make genomic medicine and its insights work for everyone. The programme will work with NHS England, grassroots communities, training institutions and other partners, to overcome the challenges caused by the lack of genetic data diversity.
This will include developing tools and approaches to enable researchers and clinicians to better interpret genomic variation to support clinical decisions in all communities, and build resilient and trusting relationships within traditionally excluded communities.
Why it matters
To date, studies of human genetics have largely focused on populations from European ancestries, which has contributed to
a world where the benefits of genomic healthcare are not shared equally. The overrepresentation of populations from ‘WEIRD’ societies (Western, Education, Industrialised, Rich and Democratic) in genomic databases has resulted in the misdiagnosis of gene-disease relationships, limited the generalisability of findings from genomic research, and reduced the evidence base for translating these findings into clinical care for all populations.
​
In short, not everyone benefits equally from the best and the latest insights in genomic medicine.